Literature DB >> 22441559

In vitro-induced response patterns of antileukemic T cells: characterization by spectratyping and immunophenotyping.

Susanne Reuther1, Helga Schmetzer, Friedhelm R Schuster, Pina Krell, Christine Grabrucker, Anja Liepert, Tanja Kroell, Hans-Jochem Kolb, Arndt Borkhardt, Raymund Buhmann.   

Abstract

Myeloid leukemic cells can be induced to differentiate into leukemia-derived dendritic cells (DCleu) regaining the stimulatory capacity of professional DCs while presenting the leukemic antigen repertoire. But so far, the induced antileukemic T-cell responses are variable both in specificity and in efficacy. In an attempt to elucidate the underlying causes of different T-cell response patterns, T-cell receptor (TR) Vβ chain rearrangements were correlated with the T cells corresponding immunophenotypic profile, as well as their proliferative response and cytolytic capacities. In three different settings, donor T cells, either human leukocyte antigen matched or mismatched (haploidentical), or autologous T cells were repeatedly stimulated with myeloid blasts or leukemia-derived DC/DCleus from the corresponding patients diseased from acute myeloid leukemia (AML). Although no significant differences in T-cell proliferation were observed, the T-cell-mediated cytolytic response pattern varied considerably and even caused blast proliferation in two cases. Spectratyping revealed a remarkable restriction (>75% of normal level) of the CD4+ or CD8+-TR repertoire of blast- or DC/DCleu-stimulated T cells. Although in absolute terms, DC/DCleu stimulation induced the highest grade of restriction in the CD8+ T-cell subset, the CD4+ T-cell compartment seemed to be relatively more affected. But most importantly, in vitro stimulation with DC/DCleu resulted into an identical TR restriction pattern (β chain) that could be identified in vivo in a patient sample 3 months after allo-SCT. Thus, in vitro tests combining functional flow cytometry with spectratyping might provide predictive information about T cellular response patterns in vivo.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22441559     DOI: 10.1007/s10238-012-0180-y

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  42 in total

1.  Dendritic cells: On the move from bench to bedside.

Authors:  F O Nestle; J Banchereau; D Hart
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

2.  Oligoclonality of CD8+ T cells in multiple sclerosis.

Authors:  J Monteiro; R Hingorani; R Peroglizzi; B Apatoff; P K Gregersen
Journal:  Autoimmunity       Date:  1996       Impact factor: 2.815

3.  A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy.

Authors:  Andrew W Lee; Tuan Truong; Kara Bickham; Jean-Francois Fonteneau; Marie Larsson; Ida Da Silva; Selin Somersan; Elaine K Thomas; Nina Bhardwaj
Journal:  Vaccine       Date:  2002-12-19       Impact factor: 3.641

4.  Flow cytometric analysis of T cell proliferation in a mixed lymphocyte reaction with dendritic cells.

Authors:  Xuan Duc Nguyen; Hermann Eichler; Alex Dugrillon; Christoph Piechaczek; Michael Braun; Harald Klüter
Journal:  J Immunol Methods       Date:  2003-04-01       Impact factor: 2.303

5.  Contributions of CD4+, CD8+, and CD4+CD8+ T cells to skewing within the peripheral T cell receptor beta chain repertoire of healthy macaques.

Authors:  J R Currier; K S Stevenson; P J Kehn; K Zheng; V M Hirsch; M A Robinson
Journal:  Hum Immunol       Date:  1999-03       Impact factor: 2.850

6.  Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods.

Authors:  Andreas Kremser; Julia Dressig; Christine Grabrucker; Anja Liepert; Tanja Kroell; Nina Scholl; Christoph Schmid; Johanna Tischer; Stefanie Kufner; Helmut Salih; Hans Jochem Kolb; Helga Schmetzer
Journal:  J Immunother       Date:  2010 Feb-Mar       Impact factor: 4.456

7.  6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.

Authors:  Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Christa Fonatsch; Helmut Löffler; Torsten Haferlach; Wolf-Dieter Ludwig; Georg Maschmeyer; Peter Staib; Carlo Aul; Andreas Gruneisen; Eva Lengfelder; Norbert Frickhofen; Wolfgang Kern; Hubert L Serve; Rolf M Mesters; Maria Cristina Sauerland; Achim Heinecke
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

8.  Improved effector function of leukemia-specific T-lymphocyte clones trained with AML-derived dendritic cells.

Authors:  Friedhelm R Schuster; Raymund Buhmann; Susanne Reuther; Bernd Hubner; Christine Grabrucker; Anja Liepert; Roland Reibke; Peter Lichtner; Ting Yang; Tanja Kroell; Hans-Jochem Kolb; Arndt Borkhardt; Helga Schmetzer
Journal:  Cancer Genomics Proteomics       Date:  2008 Sep-Oct       Impact factor: 4.069

9.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

Authors:  H J Kolb; A Schattenberg; J M Goldman; B Hertenstein; N Jacobsen; W Arcese; P Ljungman; A Ferrant; L Verdonck; D Niederwieser; F van Rhee; J Mittermueller; T de Witte; E Holler; H Ansari
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

10.  Analysis of T-cell repertoire in hepatitis-associated aplastic anemia.

Authors:  Jun Lu; Atanu Basu; J Joseph Melenhorst; Neal S Young; Kevin E Brown
Journal:  Blood       Date:  2004-02-26       Impact factor: 22.113

View more
  5 in total

Review 1.  Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia.

Authors:  Daniel Christoph Amberger; Helga Maria Schmetzer
Journal:  Transfus Med Hemother       Date:  2020-11-05       Impact factor: 3.747

Review 2.  Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.

Authors:  Anne M Dickinson; Jean Norden; Shuang Li; Ilona Hromadnikova; Christoph Schmid; Helga Schmetzer; Hans Jochem-Kolb
Journal:  Front Immunol       Date:  2017-06-07       Impact factor: 7.561

3.  Specificity, Privacy, and Degeneracy in the CD4 T Cell Receptor Repertoire Following Immunization.

Authors:  Yuxin Sun; Katharine Best; Mattia Cinelli; James M Heather; Shlomit Reich-Zeliger; Eric Shifrut; Nir Friedman; John Shawe-Taylor; Benny Chain
Journal:  Front Immunol       Date:  2017-04-13       Impact factor: 7.561

Review 4.  Research progress on dendritic cell vaccines in cancer immunotherapy.

Authors:  Jifeng Yu; Hao Sun; Weijie Cao; Yongping Song; Zhongxing Jiang
Journal:  Exp Hematol Oncol       Date:  2022-01-24

5.  Tracking global changes induced in the CD4 T-cell receptor repertoire by immunization with a complex antigen using short stretches of CDR3 protein sequence.

Authors:  Niclas Thomas; Katharine Best; Mattia Cinelli; Shlomit Reich-Zeliger; Hilah Gal; Eric Shifrut; Asaf Madi; Nir Friedman; John Shawe-Taylor; Benny Chain
Journal:  Bioinformatics       Date:  2014-08-05       Impact factor: 6.937

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.